Loading...
Loading...
Amgen
today
announced top-line results of the Phase 3 Aranesp^® (darbepoetin alfa)
RED-HF^® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.
The trial was initiated in 2006, and a total of 2,278 patients with
symptomatic systolic heart failure and anemia (hemoglobin levels ranging from
9.0-12.0 g/dL) were randomized to receive either treatment with Aranesp to
achieve a target hemoglobin of at least 13.0 g/dL (not to exceed 14.5 g/dL),
or placebo. The study did not meet its primary endpoint of reducing the
composite endpoint of time to death from any cause or first hospital admission
for worsening heart failure (Hazard Ratio 1.01, 95 percent CI 0.90, 1.13).
"The RED-HF Trial was designed and powered to evaluate whether the treatment
of anemia could improve morbidity and mortality in systolic heart failure
patients," said Michael Severino, M.D., senior vice president of Global
Development and corporate chief medical officer at Amgen. "While the study did
not meet its key endpoints, we thank the patients and investigators who
participated in RED-HF and helped answer this important question."
There were no new safety findings identified in the study. The most
frequently reported adverse events in the study were cardiac failure, dyspnea,
diarrhea, congestive heart failure and dizziness.
These summary results will be followed by full efficacy and safety analyses,
which will be shared and discussed with global regulatory agencies and
submitted for presentation at an upcoming medical meeting.
Aranesp is indicated for the treatment of anemia due to chronic kidney disease
in patients on dialysis and not on dialysis, and for the treatment of anemia
in patients with non-myeloid malignancies where anemia is due to the effect of
concomitant myelosuppressive chemotherapy, and upon initiation, there is a
minimum of two additional months of planned chemotherapy. Aranesp has not been
shown to improve quality of life, fatigue or patient well-being.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in